South Korea Expands Health Insurance for Severe Alopecia Treatments Amidst Public Debate

South Korea's national health insurance program will expand coverage for severe alopecia areata treatments starting July 1. The Ministry of Health and Welfare announced that oral medication containing the ingredient baricitinib, such as Olumiant tablets, will now be covered for adult patients suffering from severe forms of the condition.

This coverage applies to patients who have undergone at least three months of steroid treatment without a significant improvement in their alopecia severity score, or those who cannot continue treatment due to adverse effects. Specifically, patients with a severity score of 50 or higher, or those with a score between 20 and 50 along with eyebrow and eyelash loss, will qualify. Alopecia severity is measured on a scale where 100 indicates complete scalp hair loss and 0 indicates no hair loss.

For patients already undergoing treatment before the new policy takes effect, they must provide evidence that their condition met the criteria at the time of their initial prescription. Those who have been on the medication for over 36 weeks will need to submit results from that 36th week. The coverage period is limited to a maximum of two years from the policy's implementation date.

“

We have been reviewing the health insurance coverage for baricitinib since the pharmaceutical company applied last year.

A ministry official explained that the decision followed a review of the drug manufacturer's application, considering clinical literature and expert consultations. Baricitinib will join six other ingredients already covered by the national health insurance for hair loss treatment. The drug, Olumiant, currently costs over 20,000 won per pill, but the insurance coverage is expected to reduce this to around 10,000 won per pill.

Meanwhile, the government is also considering expanding insurance coverage for genetic hair loss treatments targeting younger individuals, following public discussion. Currently, health insurance covers medically induced hair loss from conditions like alopecia areata and seborrheic dermatitis, but not hair loss due to genetics or aging. Patient groups have criticized the government's approach, arguing that coverage for severe conditions should be prioritized over cosmetic concerns, intensifying the debate surrounding expanded insurance benefits for hair loss.

“

Based on clinical literature and expert advice, we have newly added baricitinib to the list of health insurance-supported treatments, bringing the total to seven ingredients.